Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 5,800 Shares of United Therapeutics Corporation $UTHR

Key Points

• Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in United Therapeutics Corporation by 24.9%, acquiring an additional 5,800 shares, bringing total holdings to 29,100 shares valued at approximately $8.97 million.
• United Therapeutics reported a decline in earnings per share for the latest quarter at $6.41, missing analysts' estimates of $6.80, and total revenue was 11.7% higher year-over-year but still fell short of expectations.
• Research analysts have set a consensus target price of $382.00 for United Therapeutics, with a mix of ratings including ten "buy" and four "hold" recommendations.

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 24.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 29,100 shares of the biotechnology company's stock after acquiring an additional 5,800 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund owned approximately 0.06% of United Therapeutics worth $8,971,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of United Therapeutics in the first quarter valued at $313,000. Allianz Asset Management GmbH increased its holdings in shares of United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after purchasing an additional 33,254 shares in the last quarter. LPL Financial LLC grew its holdings in United Therapeutics by 77.3% during the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after acquiring an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after buying an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at $227,000. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Price Performance

Shares of UTHR stock traded up $1.07 during trading hours on Friday, hitting $313.13. The stock had a trading volume of 703,795 shares, compared to its average volume of 702,087. The firm has a market capitalization of $14.13 billion, a PE ratio of 12.22, a PEG ratio of 4.74 and a beta of 0.57. The stock's 50 day moving average is $295.00 and its 200 day moving average is $308.49. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period last year, the business posted $5.85 EPS. United Therapeutics's revenue was up 11.7% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. The trade was a 13.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the transaction, the director directly owned 4,883 shares in the company, valued at $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,681 shares of company stock worth $24,618,359 over the last 90 days. Corporate insiders own 10.30% of the company's stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of research analyst reports. UBS Group upped their target price on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday. Morgan Stanley cut their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Bank of America reduced their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. Finally, JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $382.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.